News: Articles and Publications

August 17, 2022Press Release
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) — among Janssen Pharmaceutica NV, Otsuka, TB Alliance and the Bill & Melinda Gates Medical Research Institute — supporting the progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development.
August 5, 2022News Article
Gates MRI's Head of Therapeutics Development, Charles Wells, gave an interview with News Medical in which he discussed our current research into tuberculosis, the World Health Organization's new guidelines for TB care, and what inspired his career. He also spoke about Gates MRI's novel potential vaccine interventions and how we're supporting future innovative approaches to TB treatment.
March 22, 2022Podcast
Gates MRI’s CEO Emilio Emini gave an in-depth interview to the Progress, Potential, and Possibilities podcast on immunology, vaccinology, and his career in public health. He also provided an overview of Gates MRI’s research priorities and discussed a call-to-action for preparedness ahead of the next pandemic.
November 5, 2021Publication
Gates MRI’s Head of Bioassay Development and Operations, Joleen T. White, published research that provides a hypothetical case study to present an immunogenicity risk assessment for a multi-specific therapeutic as part of an Investigational New Drug (IND) application.
September 15, 2021Publication
Gates MRI’s Chief Medical Officer and Head of Development, Michael Dunne; Program Lead Mohamed Bassyouni; Head of Global Regulatory Strategy & Operations, Taryn Rogalski-Salter; Head of Translational Discovery, Jared Silverman; and Program Leads Jeroen Medema and Mohamed Bassiouni investigated whether rivaroxaban, a direct oral anticoagulant factor Xa inhibitor, would reduce coronavirus disease 2019 (COVID-19) progression. 
September 7, 2021Publication
Gates MRI’s Research Project Manager, Judith Maxwell Silverman, contributed to research demonstrating how a bioengineered yeast production strain combined with an optimized version of the SARS-CoV-2 spike protein receptor-binding domain (RBD) exhibits improved biomolecular attributes that are well-suited for further development for large-volume manufacturing of low-cost vaccine candidate.